Carcinoid Tumor: Clinical Trials

47 trials for Carcinoid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 5 terminated, 5 unknown, 3 active not recruiting. 47 Phase 2, 7 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 247Completed 28, Terminated 5, Unknown 5, Active not recruiting 3, Recruiting 3, Withdrawn 3
Phase 17Completed 3, Unknown 2, Recruiting 1, Terminated 1
Phase 31Completed 1

Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
Phase 2Active not recruitingHospices Civils de Lyon272025-10-012026-06-25
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Everolimus 5 MG - Neuroendocrine Tumors, Progression
Phase 2RecruitingAC Camargo Cancer Center1002024-04-242024-06-25
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
177Lu-DOTATOC - Neuroendocrine Tumors, Carcinoid Tumor
Phase 2WithdrawnBritish Columbia Cancer Agency2023-01-152023-02-21
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning - Gastroenteropancreatico Tumors, Neuroendocrine Tumors
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)562022-10-032026-10-16
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid
Phase 2CompletedCrinetics Pharmaceuticals Inc.362022-04-222026-03-19
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Cabozantinib, Nivolumab - Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Phase 2RecruitingFox Chase Cancer Center1112022-01-212026-07-28
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
Telotristat Ethyl Oral Tablet - Neuroendocrine Tumors
Phase 2WithdrawnUniversity of Chicago2022-01-012021-12-17
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome
Phase 2UnknownKing's College Hospital NHS Trust202020-10-012020-08-04
Cabozantinib and Nivolumab for Carcinoid Tumors
Nivolumab, Cabozantinib - Carcinoid Tumor, Carcinoid Tumor of GI System
Phase 2CompletedDana-Farber Cancer Institute192019-12-262025-01-31
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Nivolumab, Ipilimumab - Neuroendocrine Tumors, Carcinoid Tumor
Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins92018-03-092024-01-09
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Lanreotide, Y-90 microspheres - Neuroendocrine Tumors, Gastrointestinal Neoplasms
Phase 2TerminatedSCRI Development Innovations, LLC62017-07-282023-12-05
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Ramucirumab, Somatostatin Analog - Carcinoid Tumors
Phase 2CompletedDana-Farber Cancer Institute432016-06-142025-02-19
Personalized PRRT of Neuroendocrine Tumors
177Lu-Octreotate - Neuroendocrine Tumors, Carcinoid Tumor
Phase 2Active not recruitingCHU de Quebec-Universite Laval2752016-04-122024-08-21
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
pembrolizumab - Advanced Cancer, Anal Carcinoma
Phase 2Active not recruitingMerck Sharp & Dohme LLC16092015-12-182025-09-22
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
surufatinib - Tumors
Phase 1 / Phase 2CompletedHutchmed1302015-11-012024-07-10
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Ibrutinib - Carcinoid Tumors, Pancreatic NET
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute202015-10-092020-09-11
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
68Ga-DOTATOC PET/CT - Neuroendocrine Tumors, Carcinoid Tumors
Phase 2CompletedSue O'Dorisio1222015-09-012020-12-21
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Carfilzomib - Neuroendocrine Cancer
Phase 2CompletedSCRI Development Innovations, LLC622015-07-152023-12-05
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study - Carcinoid Tumor, Metastatic Carcinoid Tumor
Phase 2CompletedRoswell Park Cancer Institute322015-05-152023-12-26
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
Recombinant anti-tumor and anti-virus protein for injection (Novaferon) - Neuroendocrine Tumors
Phase 2UnknownThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences202015-05-012016-01-05

Showing 20 of 47. Sign in to see all of them.

Narrower conditions

Neuroendocrine Tumors (33)  ·  Neoplasm Metastasis (9)  ·  Adenoma, Islet Cell (8)  ·  Carcinoma (5)  ·  Carcinoma, Neuroendocrine (5)  ·  Neoplasms (4)  ·  Neuroblastoma (4)  ·  Serotonin Syndrome (4)  ·  Gastrinoma (3)  ·  Paraganglioma (3)  ·  Pheochromocytoma (3)  ·  Vipoma (3)  ·  Apudoma (2)  ·  Colorectal Neoplasms (2)

Broader conditions

Adenocarcinoma (47)  ·  Neoplasms by Histologic Type (47)  ·  Neoplasms, Germ Cell and Embryonal (47)  ·  Neoplasms, Glandular and Epithelial (47)  ·  Neoplasms, Nerve Tissue (47)  ·  Neuroectodermal Tumors (47)  ·  Neoplasms (43)  ·  Carcinoma (42)  ·  Neoplasms by Site (20)  ·  Digestive System Diseases (16)  ·  Digestive System Neoplasms (16)  ·  Endocrine Gland Neoplasms (16)  ·  Endocrine System Diseases (16)  ·  Neuroendocrine Tumors (14)  ·  Pancreatic Diseases (13)

Interventions

Everolimus (4)  ·  Nivolumab (3)  ·  cabozantinib (3)  ·  lanreotide (3)  ·  lutetium Lu 177 dotatate (3)  ·  Bevacizumab (2)  ·  Erlotinib Hydrochloride (2)  ·  Octreotide (2)  ·  Sunitinib (2)  ·  gallium Ga 68 dotatate (2)  ·  ganitumab (2)  ·  pasireotide (2)  ·  (18F)GTP1 (1)  ·  177Lu-octreotate (1)  ·  177Lu-octreotide, DOTA(0)-Tyr(3)- (1)

Sponsors

Dana-Farber Cancer Institute (5)  ·  H. Lee Moffitt Cancer Center and Research Institute (4)  ·  Novartis Pharmaceuticals (3)  ·  SCRI Development Innovations, LLC (2)  ·  Sue O'Dorisio (2)  ·  University of California, San Francisco (2)  ·  AC Camargo Cancer Center (1)  ·  Amgen (1)  ·  Arbutus Biopharma Corporation (1)  ·  Boston Medical Center (1)  ·  British Columbia Cancer Agency (1)  ·  CASI pharmaceuticals, Inc. (1)  ·  CHU de Quebec-Universite Laval (1)  ·  Callisto Pharmaceuticals (1)  ·  Columbia University (1)

Countries

United States (36)  ·  Canada (3)  ·  France (3)  ·  Poland (3)  ·  Brazil (2)  ·  China (2)  ·  Italy (2)  ·  Spain (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Germany (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  Peru (1)  ·  Sweden (1)

Top investigators

Jonathan Strosberg, M.D. (3)  ·  David Spigel, M.D. (2)  ·  Christine Hann, MD/PhD (1)  ·  Ebrahim Delpassand, M.D. (1)  ·  Emily K. Bergsland, MD (1)  ·  Francois Benard, MD (1)  ·  Frank I Lin, M.D. (1)  ·  Gary Jacob, Ph.D. (1)  ·  Jean-Mathieu Beauregard, MD,MSc,FRCPC (1)  ·  Jennifer A Chan, MD MPH (1)  ·  Jennifer Chan, MD (1)  ·  Jennifer Chan, MD, MPH (1)  ·  Jonathan Strosberg, MD (1)

Results publications

PMID 23516312, PMID 25376618, PMID 26769865, PMID 28153957, PMID 29181270, PMID 30506283, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34990208, PMID 35114169, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36395401, PMID 36748723, PMID 37074571, PMID 39500789, PMID 39834129, PMID 39979665, PMID 40121391, PMID 41920388

NIH funding

2015 (1)